吉西他滨联合帕唑帕尼二线治疗晚期平滑肌肉瘤的II期研究
LMS03是一项法国肉瘤组开放标签多中心单组II期研究,评估吉西他滨联合帕唑帕尼后帕唑帕尼维持治疗在蒽环类失败后的晚期平滑肌肉瘤患者中的疗效与耐受性。106例患者纳入,9个月无进展生存率为32.1%(95%CI 23.1-41.1),未达到预设的44%有希望阈值。研究认为该联合方案对晚期平滑肌肉瘤患者无获益。
要点
- 9个月PFS率为32.1%,低于预设的44%有希望阈值,研究未达主要终点
- 中位PFS为6.5个月(95%CI 5.6-8.2),中位OS为22.4个月(95%CI 16.9-26.5)
- 最常见3-4级不良事件为血液学毒性
核心结论
- LMS03研究未能证明吉西他滨联合帕唑帕尼后帕唑帕尼维持治疗对晚期平滑肌肉瘤患者有益。
研究设计与样本
- 开放标签多中心单组II期研究,纳入106例ECOG≤2、一线多柔比星化疗失败后的转移性平滑肌肉瘤患者。
主要发现
- 9个月PFS率为32.1%(95%CI 23.1-41.1),未达到预设的44%有希望阈值。
- 中位随访14.2个月,中位PFS为6.5个月(95%CI 5.6-8.2),中位OS为22.4个月(95%CI 16.9-26.5)。
- 最佳缓解率为23.8%,最常见3-4级不良事件为血液学毒性。
关键数值与推荐
- 不可接受和可能有希望的9个月PFS率分别预设为32%和44%(意向治疗人群)。
- 吉西他滨1000 mg/m2于每21天周期的第1天和第8天给药(最多8周期),联合口服帕唑帕尼每日800 mg直至疾病进展或毒性。
临床怎么用
- 对于蒽环类失败的晚期平滑肌肉瘤患者,不推荐常规使用吉西他滨联合帕唑帕尼后帕唑帕尼维持治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib (P) monotherapy. Currently, no combination therapy is better than monotherapy. LMS03 is an open-label multicentre single-group phase II study designed to assess the efficacy and tolerance of G + P in the second-line setting. PATIENTS AND METHODS: Patients (pts), ECOG ≤2, with metastatic leiomyosarcomas (LMS) after first-line doxorubicin chemotherapy failure were eligible. Pts were treated with G 1000 mg/m2 on days 1 and 8 of each 21 days (maximum eight cycles), in combination with oral daily P (800 mg), until disease progression/toxicity. 9-month progression-free survival (PFS) rate was the primary endpoint. Inacceptable and promising 9-month PFS rates were defined, in the intent-to-treat population, as 32% and 44%. RESULTS: 106 pts were included with a mean age of 59.8 years and an ECOG 0 in 63.5%; the primary tumour site was uterus in 61%. Pts were treated with P + G for a median of 3.8 mo, and P for a median of 4.2 mo. The 9-month PFS rate was 32.1% (95% CI 23.1-41.1). After a median follow-up of 14.2 months, the PFS was 6.5 months (95% CI 5.6-8.2), and the overall survival was 22.4 months (95% CI 16.9-26.5). The best response was 23.8%. The most frequent reported grade 3-4 adverse events were haematological. CONCLUSIONS: LMS03 failed to show that second-line therapy, with gemcitabine combined with pazopanib, followed by pazopanib alone, was beneficial for advanced LMS patients. Eudract N°2011-001308-36 and NCT01442662.
引用
- Pautier P, Penel N, Ray-Coquard I, et al. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). Eur J Cancer. 2019. PMID: 31835236. doi:10.1016/j.ejca.2019.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。